SPHINX31|cas:1818389-84-2|西域试剂

SPHINX31,99.12%

产品编号：Bellancom-117661| CAS NO：1818389-84-2| 分子式：C₂₇H₂₄F₃N₅O₂| 分子量：507.51

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-117661	￥900.00	杭州北京（现货）
Bellancom-117661	￥1200.00	杭州北京（现货）
Bellancom-117661	￥3500.00	杭州北京（现货）
Bellancom-117661	￥5500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SPHINX31

产品介绍

SPHINX31 是一种有效的、丝氨酸/富含精氨酸的蛋白激酶1 (SRPK1) 的选择性抑制剂，其IC₅₀ 值为 5.9 nM。SPHINX31 能够抑制富丝氨酸/精氨酸剪接因子 1 (SRSF1) 的磷酸化。SPHINX31 还能降低促血管生成基因 VEGF-A₁₆₅a 亚型的 mRNA 表达。SPHINX31 可用于研究新生血管性眼病。

生物活性

SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC₅₀ of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A₁₆₅a isoform. SPHINX31 can be used to research neovascular eye disease.

体外研究

SPHINX31 (0.3-10 μM; 24 h) significantly down-regulates the expression of VEGF-A₁₆₅a mRNA.
SPHINX31 (0.3 μM; 24 h) suppresses SRSF1 phosphorylation and nuclear localization.
SPHINX31 (0.3-10 μM; 24 h) decreases pre-tube formation and the rate of migration for human umbilical vein endothelial cells (HUVECs).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR

Cell Line:	HuCCA-1 cells
Concentration:	0.3, 1, 3 and 10 μM
Incubation Time:	24 h
Result:	Significantly down-regulated about 60% of the expression of VEGF-A₁₆₅a mRNA compared with the control cells.

Immunofluorescence

Cell Line:	HuCCA-1 cells
Concentration:	0.3 μM
Incubation Time:	24 h
Result:	Suppressed SRSF1 phosphorylation and nuclear localization, which thereby induced less expression of pro-angiogenic VEGF-A₁₆₅a in HuCCA-1 cells.

Cell Migration Assay

Cell Line:	HuCCA-1 cells
Concentration:	0.3, 1, 3 and 10 μM
Incubation Time:	24 h
Result:	Decreased pre-tube formation of the cells network area to about 50% of the control group. Decreased the rate of migration for HUVECs.

体内研究
(In Vivo)

SPHINX31 (200 μg/mL; twice daily topical eye drops) protects the retinal endothelial permeability barrier from diabetes-associated loss of integrity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Norway Brown rats (intraperitoneally injected with 50 mg/kg Streptozotocin (HY-10219) to induce type I diabetes)
Dosage:	200 μg/mL
Administration:	Twice daily topical eye drops
Result:	Reduced retinal permeability in the diabetics (7.92 ± 1.65 × 10^-4 cms^-1) less than before induction of diabetes (8.15 ± 2.33 × 10^-4 cms^-1), and less than the control group (8.85 ± 1.29 × 10^-4 cms^-1), while the diabetes group was 12.67 ± 1.09 × 10^-4 cms^-1.

体内研究

SPHINX31 (200 μg/mL; twice daily topical eye drops) protects the retinal endothelial permeability barrier from diabetes-associated loss of integrity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Norway Brown rats (intraperitoneally injected with 50 mg/kg Streptozotocin (HY-10219) to induce type I diabetes)
Dosage:	200 μg/mL
Administration:	Twice daily topical eye drops
Result:	Reduced retinal permeability in the diabetics (7.92 ± 1.65 × 10^-4 cms^-1) less than before induction of diabetes (8.15 ± 2.33 × 10^-4 cms^-1), and less than the control group (8.85 ± 1.29 × 10^-4 cms^-1), while the diabetes group was 12.67 ± 1.09 × 10^-4 cms^-1.

体内研究

SPHINX31 (200 μg/mL; twice daily topical eye drops) protects the retinal endothelial permeability barrier from diabetes-associated loss of integrity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Norway Brown rats (intraperitoneally injected with 50 mg/kg Streptozotocin (HY-10219) to induce type I diabetes)
Dosage:	200 μg/mL
Administration:	Twice daily topical eye drops
Result:	Reduced retinal permeability in the diabetics (7.92 ± 1.65 × 10^-4 cms^-1) less than before induction of diabetes (8.15 ± 2.33 × 10^-4 cms^-1), and less than the control group (8.85 ± 1.29 × 10^-4 cms^-1), while the diabetes group was 12.67 ± 1.09 × 10^-4 cms^-1.

性状

Solid

溶解性数据

In Vitro:

DMSO : 17.33 mg/mL (34.15 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9704 mL	9.8520 mL	19.7040 mL
5 mM	0.3941 mL	1.9704 mL	3.9408 mL
10 mM	0.1970 mL	0.9852 mL	1.9704 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2 mg/mL (3.94 mM); Clear solution

此方案可获得 ≥ 2 mg/mL (3.94 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2 mg/mL (3.94 mM); Clear solution

此方案可获得 ≥ 2 mg/mL (3.94 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。